Contrasting Beyondspring (BYSI) & The Competition
Beyondspring (NASDAQ: BYSI) is one of 188 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its rivals? We will compare Beyondspring to related businesses based on the strength of its risk, dividends, analyst recommendations, profitability, valuation, earnings and institutional ownership.
This is a breakdown of recent ratings and target prices for Beyondspring and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Beyondspring currently has a consensus target price of $54.50, suggesting a potential upside of 78.69%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 14.13%. Given Beyondspring’s stronger consensus rating and higher possible upside, equities analysts plainly believe Beyondspring is more favorable than its rivals.
This table compares Beyondspring and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares Beyondspring and its rivals top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Beyondspring Competitors||$218.26 million||-$39.73 million||-61.77|
Beyondspring’s rivals have higher revenue, but lower earnings than Beyondspring.
Institutional and Insider Ownership
1.2% of Beyondspring shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 14.6% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Beyondspring beats its rivals on 7 of the 11 factors compared.
Beyondspring Company Profile
BeyondSpring Inc. is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). Plinabulin has also entered in a Phase I/II clinical trials to investigate its therapeutic potential in combination with the immuno-oncology agent nivolumab. The Company’s BPI-002 program is based on an oral small molecule agent, which induces T-cell activation. The Company’s IkappaB kinase (IKK) program, BPI-003, is based on a small molecule inhibitor of IKK, a protein kinase.
Receive News & Ratings for Beyondspring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyondspring and related companies with MarketBeat.com's FREE daily email newsletter.